My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
About Us
Plans & Pricing

Leerink Partners Remains a Hold on Pfizer (PFE)

Leerink Partners analyst Geoff Porges maintained a Hold rating on Pfizer (PFEResearch Report) on September 7 and set a price target of $49.00. The company’s shares closed last Wednesday at $43.95.

According to, Porges is a 3-star analyst with an average return of 2.6% and a 48.4% success rate. Porges covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Vertex Pharmaceuticals, and Theravance Biopharma.

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $45.55, implying a 3.5% upside from current levels. In a report issued on August 24, Morgan Stanley also reiterated a Hold rating on the stock with a $45.00 price target.

See today’s analyst top recommended stocks >>

Pfizer’s market cap is currently $246.4B and has a P/E ratio of 18.80. The company has a Price to Book ratio of -34.45.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Read More on PFE: